Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Proteomics International Laboratories Ltd. ( (AU:PIQ) ) has issued an update.
Proteomics International Laboratories Ltd has launched its predictive blood test, PromarkerD, in the US at the American Diabetes Association’s Scientific Sessions. This test, which can predict the onset of diabetes-related chronic kidney disease up to four years in advance, is initially available in California. It represents a significant commercial opportunity in the US, aiming to improve patient outcomes and reduce healthcare costs associated with DKD. The launch is part of the company’s broader strategy to engage with healthcare providers and expand its market presence through direct-to-consumer and partner sales avenues.
The most recent analyst rating on (AU:PIQ) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Proteomics International Laboratories Ltd. stock, see the AU:PIQ Stock Forecast page.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd is a leader in precision diagnostics, focusing on innovative medical tests. The company is known for its development of PromarkerD, a blood test for predicting diabetes-related chronic kidney disease (DKD). Their market focus includes direct-to-consumer engagement and partnerships within the healthcare industry.
Average Trading Volume: 193,169
Technical Sentiment Signal: Sell
Current Market Cap: A$61.32M
For detailed information about PIQ stock, go to TipRanks’ Stock Analysis page.